UNIT OF SYNTHESIS & BIOMEDICAL APPLICATIONS OF PEPTIDES
Group Leader: Isabel Haro
There is an exponential growth in the application of synthetic peptides as new therapeutic or diagnostic agents since, on the one hand, they are molecules that do not usually present as many problems of toxicity or accumulation in tissues as those of a non-peptidic nature, and on the other, they can make structural modifications and incorporate non-proteinogenic motifs and, in this way try to obtain compounds with the possibility of being used in Biomedicine. In the Unit of Synthesis and Biomedical Applications of Peptides (USiBAP) the scientific interests focus on the chemistry of peptides under three different points of view: design, synthesis and study of the possible therapeutic value of peptide molecules. The general objectives of the USiBAP research are summarized in the use of synthetic peptides in the field of Biomedicine, both in the improvement of current diagnostic systems and in the design of new therapeutic targets.
New entry peptide inhibitors of human immunodeficiency virus type 1 (HIV-1), with a possible additional prophylactic value as a therapeutic vaccine
The current interest in peptide inhibitors of fusion and viral entry, as new future anti-HIV-1 drugs, is growing exponentially given that, on the one hand, they have applicability in combination therapies or when resistance to other antiretroviral drugs appear and on the other, since they act before the virus enters the cell, they may have the same potential, as pre-exposure prophylaxis, than the induction of immunity provided by a vaccine. The development of microbicides as an alternative to existing prevention methods is considered of paramount importance. In this sense, this line of research proposes the synthesis of new peptides and the design of nanosystems to increase the anti-viral activity and the pharmacological properties of the peptides that result in entry inhibitors. On the other hand, we study the structural and interaction characteristics with membrane models of the inhibitory peptides that are determinant for their activity, using NMR and biophysical tests (Project of the RETOS Program funded by the Ministry of Economy and Competitiveness)
Development of new improved serological systems for the diagnosis and prognosis of rheumatoid arthritis
Scheme of a peptide microarray assay for the detection of specific ACPAs.
Rheumatoid arthritis (RA) is a chronic, disabling, inflammatory joint disease that has been estimated to affect 0.5-1% of the world’s population. There is a clear interest in improving both the accuracy of specific tests for diagnosis, and its early differentiation from other rheumatic diseases affecting the joints and connective tissue; especially in the case of patients with a worse prognosis or in those with an earlier development of the disease. In our group we carry out the synthesis of peptides with different amino acid combinations (Citrulline / HomoCitrulline), which are the consequence of post-translational modifications related to RA. We are working on the design of new peptides in their linear, cyclic version and in the form of chimeric molecules constituted by domains of several of the proteins that are abundant in the rheumatoid synovium. By means of the simultaneous analysis of the target peptides incorporated in a microarray, it is intended to obtain “biological fingerprints” of serum autoantibodies that can allow the identification of subsets of patients with certain clinical characteristics, different prognoses or that respond well or have adverse effects to certain therapeutic interventions. We work in close collaboration with the Arthritis Unit of the Rheumatology Service of the Hospital Clínic of Barcelona in projects financed by the Ministry of Economy and Competitiveness (RETOS Program and Thematic Networks of Cooperative Research in Health), for the Hospital Clínic de Barcelona and for a multinational pharmaceutical industry.
Controlled release peptide nanosystems for ocular administration of drugs
The administration of drugs in ocular tissues is problematic due to the low bioavailability of them in the current topical formulations. The objective of this line of research is to obtain new administration systems based on liposomes and nanoparticles, which use peptides for their targeting, and which can ensure low irritation, adequate bioavailability and compatibility with ocular tissues. We work in collaboration with the Department of Pharmacy, Pharmaceutical Technologies and Physicochemistry of the Faculty of Pharmacy of the University of Barcelona.
Synthesis of (A) PLGA-NPs-PEG-Peptide and (B) PLGA-PEG-Peptide polymer followed NPs preparation
Draize test after instillation of PLGA-PEG-POD-NPs (A) and inflammation induced by Sodium arachidonate (B)
Scientific staff
Isabel Haro
Scientific Researcher
isabel.haro@iqac.csic.es
Mª José Gómara
Tenured Scientist
mariajose.gomara@iqac.csic.es
Lab people
Elena Sánchez
Lectured professor UB
Cristina García
Predoctoral Researcher
cristina.garcia@iqac.csic.es
Gerard Esteruelas
Presdoctoral Researcher
gerard.esteruelas@iqac.csic.es
Mayra Fuertes
Predoctoral Researcher
mayra.fuertes@iqac.csic.es
Ruth Galindo
Predoctoral Researcher
Mª José Bleda
Specialist Technician
mjose.bleda@iqac.csic.es
- Atorvastatin-loaded peptide amphiphiles against corneal neovascularization Elena Sánchez-López, Maria José Gómara & Isabel Haro2023 Future Medicine Ltd
- Novel customized age-dependent corneal membranes and interactions with biodegradable nanoparticles loaded with dexibuprofen
Esteruelas, G., Ortiz, A., Prat, J., Vega, E., Muñoz-Juncosa, M., López, M.L.G., Ettcheto, M., Camins, A., Sánchez-López, E., Pujol, M.
Colloids and Surfaces B: Biointerfaces, 228, 2023
- Riluzole-Loaded Nanostructured Lipid Carriers for Hyperproliferative Skin Diseases
Llorente, X., Esteruelas, G., Bonilla, L., Agudelo, M.G., Filgaira, I., Lopez-Ramajo, D., Gong, R.C., Soler, C., Espina, M., García, M.L., Manils, J., Pujol, M., Sánchez-López, E.
International Journal of Molecular Sciences, 24 (9), art. no. 8053, 2023
- Cell penetrating peptides-functionalized Licochalcone-A-loaded PLGA nanoparticles for ocular inflammatory diseases: Evaluation of in vitro anti-proliferative effects, stabilization by freeze-drying and characterization of an in-situ forming gel
Ruth M. Galindo-Camacho, Isabel Haro, María J. Gòmara, Marta Espina, Joel Fonseca, Carlos Martins-Gomes, Antoni Camins, Amélia M. Silva, María L. García, Eliana B. Souto
International Journal of Pharmaceutics 639 (2023)
- Precision Medicines for Retinal Lipid Metabolism-Related Pathologies
Ana, R.D., Gliszczyńska, A., Sanchez-Lopez, E., Garcia, M.L., Krambeck, K., Kovacevic, A., Souto, E.B.
Journal of Personalized Medicine, 13 (4), art. no. 635, 2023
- A novel rhein-huprine hybrid ameliorates disease-modifying properties in preclinical mice model of Alzheimer’s disease exacerbated with high fat diet
Espinosa-Jiménez, T., Cano, A., Sánchez-López, E., Olloquequi, J., Folch, J., Bulló, M., Verdaguer, E., Auladell, C., Pont, C., Muñoz-Torrero, D., Parcerisas, A., Camins, A., Ettcheto, M.
Cell and Bioscience, 13 (1), art. no. 52, 2023
- Conventional and PEGylated Liposomes as Vehicles of Copaifera sabulicola
Blanco, I.M.R., Barbosa, R.D.M., Borges, J.M.P., de Melo, S.A.B.V., El-Bachá, R.D.S., Viseras, C., Severino, P., Sanchez-Lopez, E., Souto, E.B., Cabral-Albuquerque, E.
Pharmaceutics, 15 (2), art. no. 671, 2023.
- Exosomes-Based Nanomedicine for Neurodegenerative Diseases: Current Insights and Future Challenges
Cano, A., Muñoz-Morales, Á., Sánchez-López, E., Ettcheto, M., Souto, E.B., Camins, A., Boada, M., Ruíz, A.
Pharmaceutics, 15 (1), art. no. 298, 2023.
- Perspectives of the Application of Non-Steroidal Anti-Inflammatory Drugs in Cancer Therapy: Attempts to Overcome Their Unfavorable Side Effects
Thiruchenthooran, V., Sánchez-López, E., Gliszczyńska, A.
Cancers, 15 (2), art. no. 475, 2023.
- Extracellular vesicles, the emerging mirrors of brain physiopathology
Cano, A., Ettcheto, M., Bernuz, M., Puerta, R., de Antonio, E.E., Sánchez-López, E., Souto, E.B., Camins, A., Martí, M., Pividori, M.I., Boada, M., Ruiz, A.
International Journal of Biological Sciences, 19 (3), pp. 721-743.
- Implications of Post-Translational Modifications in Autoimmunity with Emphasis on Citrullination, Homocitrullination and Acetylation for the Pathogenesis, Diagnosis and Prognosis of Rheumatoid Arthritis
Isabel Haro, Raimon Sanmartí and María J. Gómara
nt. J. Mol. Sci. 2022, 23(24), 15803
- Polymeric nanoparticles as drug delivery systems for dementia
Esteruelas, G., Souto, E.B., Cano, A., Ettcheto, M., Espina, M., Camins, A., García, M.L., Sánchez-López, E.
Nanomedicine-Based Approaches for the Treatment of Dementia, pp. 89-114.
- Protein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for neurological disorders
Olloquequi, J., Cano, A., Sanchez-López, E., Carrasco, M., Verdaguer, E., Fortuna, A., Folch, J., Bulló, M., Auladell, C., Camins, A., Ettcheto, M.
Biomedicine and Pharmacotherapy, 155, art. no. 113709, 2022
- Customized cationic nanoemulsions loading triamcinolone acetonide for corneal neovascularization secondary to inflammatory processes
Fernandes, A.R., Vidal, L.B., Sánchez-López, E., dos Santos, T., Granja, P.L., Silva, A.M., Garcia, M.L., Souto, E.B.
International Journal of Pharmaceutics, 623, art. no. 121938, 2022
- Nanoparticles in Endodontics Disinfection: State of the Art
Roig-Soriano, X., Souto, E.B., Elmsmari, F., Garcia, M.L., Espina, M., Duran-Sindreu, F., Sánchez-López, E., González Sánchez, J.A.
Pharmaceutics, 14 (7), art. no. 1519,
- Peroxisomal Proliferator-Activated Receptor β/δ Deficiency Induces Cognitive Alterations
Espinosa-Jiménez, T., Busquets, O., Cano, A., Sánchez-López, E., Verdaguer, E., Parcerisas, A., Olloquequi, J., Auladell, C., Folch, J., Wahli, W., Vázquez-Carrera, M., Camins, A., Ettcheto, M.
Frontiers in Pharmacology, 13, art. no. 902047, 2022
- Response to: 'Autoantibodies and interstitial lung disease in rheumatoid arthritis: towards a 'mix-and-match' approach' by Alunno et al
Castellanos-Moreira, R., Rodríguez-García, S.C., Haro, I., Sanmarti, R.
Annals of the rheumatic diseases, 81 (4), p. e54. 2022
- The synovial and blood monocyte DNA methylomes mirror prognosis, evolution, and treatment in early arthritis
de la Calle-Fabregat, C., Rodríguez-Ubreva, J., Ciudad, L., Ramírez, J., Celis, R., Azuaga, A.B., Cuervo, A., Graell, E., Pérez-García, C., Díaz-Torné, C., Salvador, G., Gómez-Puerta, J.A., Haro, I., Sanmartí, R., Cañete, J.D., Ballestar, E.
JCI Insight, 7 (9), art. no. e158783, 2022
- QuEChERS-based analytical methods developed for LC-MS/MS multiresidue determination of pesticides in representative crop fatty matrices: Olives and sunflower seeds
García-Vara, M., Postigo, C., Palma, P., Bleda, M.J., López de Alda, M.
Food Chemistry, 386, art. no. 132558, 2022
- Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation
Ruth Galindo, Elena Sánchez-López, María José Gómara, Marta Espina, Miren Ettcheto, Amanda Cano, Isabel Haro, Antoni Camins and María Luisa García
Pharmaceutics 2022, 14(2), 285;
- Peptides Bearing Multiple Post-Translational Modifications as Antigenic Targets for Severe Rheumatoid Arthritis Patients
Cristina García-Moreno, María J. Gómara, Raúl Castellanos-Moreira, Raimon Sanmartí and Isabel Haro
Int. J. Mol. Sci. 2021, 22(24), 13290
- Peptides bearing multiple post-translational modifications as antigenic targets for severe rheumatoid arthritis patients
García-Moreno, C., Gómara, M.J., Castellanos-Moreira, R., Sanmartí, R., Haro, I.
International Journal of Molecular Sciences, 22 (24), art. no. 13290, 2021
- Peptide Amphiphilic-Based Supramolecular Structures with Anti-HIV-1 Activity
Maria J. Gómara, Ramon Pons, Carolina Herrera, Paul Ziprin, and Isabel Haro
Bioconjugate Chem. 32 (9), pp. 1999-2013. 2021
- Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy
Julià, A., López-Lasanta, M., Blanco, F., Gómez, A., Haro, I., Mas, A.J., Erra, A., Vivar, M.L.G., Monfort, J., Sánchez-Fernández, S., González, I., Alperi, M., Castellanos-Moreira, R., Fernández-Nebro, A., Díaz-Torné, C., Palau, N., Lastra, R., Lladós, J., Sanmartí, R., Marsal, S
BMC Musculoskeletal Disorders, 22 (1), art. no. 372, 2021
- Palindromic rheumatism: a unique and enigmatic entity with a complex relationship with rheumatoid arthritis
Raimon Sanmartí, Isabel Haro & Juan D Cañete
Frontiers in Medicine, 8, art. no. 657983, 2021
- Occurrence and human health risk assessment of antibiotics and their metabolites in vegetables grown in field-scale agricultural systems
Tadić, Bleda Hernandez, M.J., Cerqueira, F., Matamoros, V., Piña, B., Bayona, J.M.
Journal of Hazardous Materials, 401, art. no. 123424, 2021
- Anti-carbamylated protein antibody isotype pattern differs between palindromic rheumatism and rheumatoid arthritis
Raul Castellanos-Moreira, Sebastian C. Rodriguez-Garcia, Sonia Cabrera-Villalba, María José Gomara, Georgina Salvador, Virginia Ruiz-Esquide, Julio Ramirez, Jose Inciarte-Mundo, Rosa Morla, Cristina Garcia-Moreno, Andrea Cuervo, Jose A. Gómez-Puerta, Juan D. Cañete, Isabel Haro, Raimon Sanmarti
Therapeutic Advances in Musculoskeletal Disease, 2020
- Nanotechnology-based platforms for vaginal delivery of peptide microbicides
Sanchez-Lopez, E., Gomara, M.J., Haro, I.
Current Medicinal Chemistry, 28 (22), pp. 4356-4379. 2021
- Is Auto-Antibody Expansion the Turning Point Between Idiopathic Pulmonary Fibrosis and Rheumatoid Arthritis?
Castellanos-Moreira, R., Rodriguez-Garcia, S.C., Hernandez-Gonzalez, F., Sellares, J., Haro, I., Sanmarti, R.
Chest, 158 (4), pp. 1777-1778. 2020
- Importance of structure-based studies for the design of a novel HIV-1 inhibitor peptide
María J. Gomara , Yolanda P erez, Patricia Gomez‑Gutierrez, Carolina Herrera, Paul Ziprin, Javier P. Martinez, Andreas Meyerhans, Juan J. P erez & Isabel Haro
Scientific Reports volume 10, Article number: 14430 (2020)
- Lipid Vesicles Loaded with an HIV-1 Fusion Inhibitor Peptide as a Potential Microbicide
Elena Sánchez-López, Anna Paús, Ignacio Pérez-Pomeda, Ana Calpena, Isabel Haro and María José Gómara
Pharmaceutics 2020, 12(6), 502
- Current advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases
Cano, A., Sánchez-López, E., Ettcheto, M., López-Machado, A., Espina, M., Souto, E.B., Galindo, R., Camins, A., García, M.L., Turowski, P.
Nanomedicine, 15 (12), pp. 1239-1261, 2020
- Anti-carbamylated protein antibody isotype pattern differs between palindromic rheumatism and rheumatoid arthritis
Raul Castellanos-Moreira, Sebastian C. Rodriguez-Garcia, Sonia Cabrera-Villalba, María José Gomara, Georgina Salvador, Virginia Ruiz-Esquide, Julio Ramirez, Jose Inciarte-Mundo, Rosa Morla, Cristina Garcia-Moreno, Andrea Cuervo, Jose A. Gómez-Puerta, Juan D. Cañete, Isabel Haro, Raimon Sanmarti
Annals of the Rheumatic Diseases, 79 (5), pp. 587-594. 2020
- Rheumatoid Arthritis Initiating as Palindromic Rheumatism: A Distinct Clinical Phenotype?
Castellanos-Moreira, R., Rodriguez-Garcia, S.C., Gómez-Puerta, J.A., Ruiz-Esquide, V., Camacho, O., Ramírez, J., Cuervo, A., Morlà, R., Cañete, J.D., Haro, I., Sanmarti, R.
The Journal of Rheumatology May 2020, 47 (5) 652-657
- "Relationship between rheumatoid arthritis and interstitial lung disease is a ‘two-way street’. Response to: ‘Autoantibodies and interstitial lung disease in rheumatoid arthritis: towards a ‘mix-and-match’ approach’ by Alunno et al "
Raul Castellanos-Moreira, Sebastian Cruz Rodríguez-García, Isabel Haro, Raimon Sanmarti
Annals of the Rheumatic Diseases 2020
- Anti-carbamylated proteins antibody repertoire in rheumatoid arthritis: evidence of a new autoantibody linked to interstitial lung disease
Castellanos-Moreira, R., Rodríguez-Garciá, S.C., Gomara, M.J., Ruiz-Esquide, V., Cuervo, A., Casafont-Solé, I., Ramírez, J., Holgado, S., Gómez-Puerta, J.A., Cañete, J.D., Haro, I., Sanmarti, R.
Annals of the Rheumatic Diseases, 2020
- Effective In Vivo Topical Delivery of siRNA and Gene Silencing in Intact Corneal Epithelium Using a Modified Cell-Penetrating Peptide
Davide Schiroli, María J.Gómara, Eleonora Maurizi, Sarah D.Atkinson, Laura Mairs, Kathleen A.Christie, Diego F.Cobice, Cian M.McCrudden, M. Andrew Nesbit, Isabel Haro, Tara Moore
Molecular Therapy - Nucleic Acids, Volume 17, 6 September 2019, Pages 891-906
- Rheumatoid Arthritis Initiating as Palindromic Rheumatism: A Distinct Clinical Phenotype?
Raul Castellanos-Moreira, Sebastian C. Rodriguez-Garcia, Jose Alfredo Gómez-Puerta, Virginia Ruiz-Esquide, Oscar Camacho, Julio Ramírez, Andrea Cuervo, Rosa Morla, Juan D. Cañete, Isabel Haro and Raimon Sanmarti
The Journal of Rheumatology August 2019, jrheum.190061
- Development of a multiplex assay based on chimeric citrullinated peptides as proof of concept for diagnosis of rheumatoid arthritis
Cristina García-Moreno, María José Gómara, María José Bleda, Raimon Sanmartí, Isabel Haro
PLoS ONE 14(5): e0215927. 2019
- Peptide Assembly on the Membrane Determines the HIV-1 Inhibitory Activity of Dual-Targeting Fusion Inhibitor Peptides
Maria J. Gomara, Yolanda Perez, Javier P. Martinez, Ramon Barnadas-Rodriguez, Anke Schultz, Hagen von Briesen, Alex Peralvarez-Marin, Andreas Meyerhans & Isabel Haro
Scientific Reportsvolume 9, Article number: 3257 (2019)
- Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant
Carolina Beltran-Pavez, Carolina B. Ferreira, Alberto Merino-Mansilla, Amanda Fabra-Garcia, Maria Casadella, Marc Noguera-Julian, Roger Paredes, Alex Olvera, Isabel Haro, Christian Brander, Felipe Garcia, Jose M. Gatell, Eloisa Yuste, Victor Sanchez-Merino
PLoS ONE, December 19, 2018
- Design, Characterization, and Biopharmaceutical Behavior of nanoparticles Loaded with an HIV-1 Fusion Inhibitor Peptide
Ariza-Sáenz, M., Espina, M., Calpena, A., Gómara, M.J., Pérez-Pomeda, I., Haro, I., García, M.L.
Mol. Pharmaceutics 2018, 15, 5005−5018
- Glioblastoma Bystander Cell Therapy: Improvements in Treatment and Insights into the Therapy Mechanisms
Guerra-Rebollo, M., Nogueira de Moraes, C., Alcoholado, C., Soler-Botija, C., Sanchez-Cid, L., Vila, O.F., Meca-Cortés, O., Ramos-Romero, S., Rubio, N., Becerra, J., Blanco, J., Garrido, C.
Molecular Therapy - Oncolytics, 11, pp. 39-51. 2018
- Comparative study of the diagnostic and prognostic value of antibodies against chimeric citrullinated synthetic peptides and CCP3 / CCP3.1 assays
María J. Gómara, Javier Rodríguez, María J. Bleda, J. Pablo Salvador, Raimon Sanmartí and Isabel Haro
Clinical Chemistry and Laboratory Medicine, 52(2), 285-293 (2018)
- Structural study of a new HIV-1 entry inhibitor and interaction with the HIV-1 fusion peptide in dodecylphosphocholine micelles
Yolanda Pérez, María J. Gómara, Eloísa Yuste, Patricia Gómez-Gutiérrez, Juan J. Pérez, Isabel Haro
Chemistry: A European Journal, 23, 11703-11713 (2017)
- Penetration of polymeric nanoparticles loaded with an HIV-1 inhibitor peptide derived from GB virus C using a vaginal mucosa model
Martha Ariza, Marta Espina, Ana C. Calpena, Nuria Bolaños, Maria J. Gómara, Isabel Haro, María L. García
European Journal Pharmaceutics and Biopharmaceutics, 120, 98-106 (2017)
- Differing specificities and isotypes of anti-citrullinated peptide/protein antibodies in palindromic rheumatism and rheumatoid arthritis
Sonia Cabrera-Villalba, María José Gomara, Juan Cañete, Julio Ramírez, Georgina Salvador, Virginia Ruiz-Esquide, Maria Victoria Hernandez, Jose Inciarte-Mundo, Isabel Haro, Raimon Sanmarti
Arthritis Research & Therapy, 19:141(2017)
- Lipid raft-like liposomes used for targeted delivery of a chimeric entry-inhibitor peptide with anti-HIV-1 activity
María José Gómara, Ignacio Pérez-Pomeda, José María Gatell, Victor Sánchez-Merino, Eloisa Yuste, Isabel Haro
Nanomedicine: Nanotechnology, Biology and Medicine 13(2), 601-609 (2017)
- Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor
María J Gómara, Víctor Sánchez-Merino, Anna Paús, Alberto Merino- Mansilla, José M Gatell, Eloísa Yuste, Isabel Haro
Biochim. Biophys. Acta. 1860, 1139–1148 (2016)
- Conjugation of cell-penetrating peptides with poly(lactic-co-glycolic acid)-polyethylene glycol nanoparticles improves ocular delivery
Vasconcelos, E. Vega, Y. Pérez, MJ. Gómara, ML. García, I. Haro
Int. J. Nanomedicine, 10, 609-631 (2015)
- The use of citrullinated peptides for the diagnosis and prognosis of rheumatoid arthritis
Isabel Haro and Maria J. Gómara
Current Topics in Medicinal Chemistry, 14, 2729-2733 (2014)
- A cyclic GB virus C peptide with anti-HIV-1 activity targets the fusion peptide of HIV-1
Ramona Galatola, Aimee Vasconcelos, Yolanda Pérez, Antonio Cruz, Montserrat Pujol, María A. Alsina, María J. Gómara, Isabel Haro
Eur. J. Med. Chem. 86, 589-604 (2014)
- HIV-1 inhibiting capacity of novel forms of presentation of GB virus C peptide domains is enhanced by coordination to gold compounds
María J. Gómara, Ramona Galatola, Alejándro Gutiérrez, María C. Gimeno, José M. Gatell, Víctor Sánchez-Merino, Eloísa Yuste, Isabel Haro
Curr. Med. Chem, 21(2), 238-250 (2014)
- Design and application of GB virus C (GBV-C) peptide microarrays for diagnosis of GBV-C/HIV-1 co-infection
Leticia Fernández, M. José Bleda, M. José Gómara, Isabel Haro
Anal Bioanal Chem, 405, 3973-3982 (2013)
- Antibodies against β-fibrin synthetic peptides: study of their association with the immunogenetic background and disease course of Rheumatoid Arthritis patients
Haro, M.J. Gómara, M.L. Pérez, J.A. Gómez-Puerta, O. Viñas, G. Ercilla, R. Sanmartí
Eur. J. Med. Chem. 46, 1095-1102 (2011)
- Carbon nanotube composite peptide-based biosensors as putative diagnostic tools for rheumatoid arthritis
María de Gracia Villa, Cecilia Jiménez-Jorquera, Isabel Haro, Maria José Gomara, Raimon Sanmartí, César Fernández-Sánchez and Ernest Mendoza
Biosensors & Bioelectronics 27, 113-118 (2011)
- The use of chimeric vimentin citrullinated peptides for the diagnosis of rheumatoid arthritis
Morteza Malakoutihak, Maria J. Gómara, Jose A. Gómez-Puerta, Raimon Sanmartí, Isabel Haro
J.Med. Chem 54, 7486-7492 (2011)
- Effect of synthetic peptides belonging to E2 envelope protein of GB virus C on human immunodeficiency virus type 1 infection
E.Herrera, S. Tenckhoff, M.J. Gómara, R. Galatola, M.J. Bleda, C. Gil, G. Ercilla, J.M. Gatell, H. Tillmann, I. Haro
J.Med. Chem. 53, 6054-6063 (2010)
- Effects of abatacept on the progression to rheumatoid arthritis in patients with palindromic rheumatism
Entidad financiadora: Bristol-Myers Squibb
Investigadores principales: Dr. Raimon Sanmartí / Dra. Isabel Haro
Duración: 2018-2020
El proyecto se enmarca en un ensayo clínico multicéntrico. En la Unidad de Síntesis y Aplicaciones Biomédicas de Péptidos, se diseñan nuevos inmunoensayos basados en péptidos sintéticos y/o proteínas modificadas. Se estudian autoanticuerpos anti-péptidos/proteínas citrulinadas, autoanticuerpos anti-péptidos/proteínas carbamiladas y/o autoanticuerpos mixtos en pacientes de Artritis Reumatoide y Reumatismo Palindrómico.
- Red de Investigación en Inflamación y Enfermedades Reumáticas (RIER)
Entidad financiadora: Ministerio de Economía, Industria y Competitividad. Programa Redes Temáticas de Investigación Cooperativa en salud (RETICS)
Investigador coordinador: Dr. Jose L. Pablos (Hospital 12 Octubre)
Duración: 2017-2020.
La Red de Investigación en Inflamación y Enfermedades Reumáticas (RIER) aborda múltiples aspectos del conocimiento básico, clínico y terapéutico de la artritis reumatoide, como modelo de enfermedad inflamatoria crónica que tiene un enorme impacto social y sanitario. La RIER tiene una clara vocación traslacional, y persigue un conocimiento orientado a proporcionar nuevas herramientas diagnósticas, pronósticas y terapéuticas que permitan progresar hacia un abordaje más individualizado y eficaz de las enfermedades reumáticas. En este contexto, la RIER organiza numerosas reuniones científicas nacionales e internacionales
- Anticuerpos frente a péptidos carbamilados en la artritis reumatoide: valor diagnóstico y asociación con respuesta terapéutica
Entidad financiadora: Hospital Clínic (Premi “Emili Letang”, Fi de Residència)
Entidades participantes: Hospital Clínic, IQAC-CSIC
Investigador coordinador: Dr. Raimon Sanmartí / Dr. Raul A. Castellanos
Duración: 2018
Comúnmente se emplean dos sistemas, basados en la detección de autoanticuerpos, para diagnosticar/clasificar la Artritis Reumatoide (AR); el factor reumatoide (RF) y los anticuerpos contra péptidos/proteínas citrulinadas (ACPA). Los ACPA se consideran altamente específicos de la enfermedad, tienen buenas propiedades diagnósticas, están asociados con una enfermedad más grave, tienen un papel patogenético y son biomarcadores de respuesta terapéutica a determinados fármacos biológicos. Sin embargo existe un 20-30% de AR negativos para FR y/o ACPA. Recientemente, se ha descrito un nuevo sistema de autoanticuerpos dirigidos contra proteínas carbamiladas (anticuerpos anti-CarP). En el proyecto se analiza el valor diagnóstico de los anti-CarP en la AR, así como su papel como marcador de respuesta terapéutica a determinados fármacos que se emplean en el tratamiento de la AR.
- Diseño, síntesis y aplicaciones biomédicas de péptidos: inhibidores de entrada del HIV-1 y diagnóstico de la artritis reumatoide
Referencia: CTQ2015-63919-R
Entidad Financiadora: MINECO/FEDER
Investigadora principal: Dra. Isabel Haro
Duración: 2016-2018
Existe un crecimiento exponencial en la aplicación de péptidos sintéticos como nuevos agentes terapéuticos o de diagnóstico ya que, por un lado son moléculas que no suelen presentar tantos problemas de toxicidad o de acumulación en tejidos como las de naturaleza no peptídica, y por otro, se pueden realizar modificaciones estructurales e incorporar motivos no proteinogénicos para, de este modo, tratar de obtener compuestos con posibilidad de ser empleados en Biomedicina.
Los objetivos generales de este proyecto son el diseño, la síntesis y el estudio de aplicaciones biomédicas de péptidos para su empleo, específicamente, en la obtención de nuevos inhibidores peptídicos de entrada del HIV-1, con un posible valor profiláctico adicional como vacuna terapéutica; y en el desarrollo de nuevos sistemas serológicos mejorados para el diagnóstico y pronóstico de la artritis reumatoide.
